Sp268
OPTIMAL MANAGEMENT OF NON-EOE EGID
Date
May 6, 2023
Explore related products in the following collection:
Tracks
Related Products
SMALL GROUP DISCUSSIONS IN ROOM
This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field…
EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
<i>THE SEVERITY OF REDUCED ESOPHAGEAL DISTENSIBILITY PARALLELS EOSINOPHILIC DISEASE DURATION</i>
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy…
CASED BASED DISCUSSION
SOCIETY: AGA